Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men

Korean Journal of Urology

Volumn 56, Issue 4, 2015, Pages 310-317

  Saad, Farid ^a,b   Yassin, Aksam ^b,c,d   Haider, Ahmad ^e   Doros, Gheorghe ^f   Gooren, Louis ^g  

^a BAYER PHARMA AG   (Germany)

^b GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^c Institute for Urology and Andrology   (Germany)

^d DRESDEN INTERNATIONAL UNIVERSITY   (Germany)

^e Private Urology Practice   (Germany)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Body weight; Erectile dysfunction; Hypogonadism; Testosterone

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; LIPID; LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE UNDECANOATE; ANDROGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG SAFETY; HEMATOCRIT; HUMAN; HYPOGONADISM; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PARAMETERS; PROSTATE VOLUME; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEXUAL FUNCTION; URINARY PARAMETER; URINARY TRACT FUNCTION; WAIST CIRCUMFERENCE; AGE; ANALOGS AND DERIVATIVES; ANTHROPOMETRY; DRUG EFFECTS; DRUG MONITORING; GERMANY; MIDDLE AGED; ONSET AGE; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROSTATE; PSYCHOLOGY; REGISTER; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

AGE FACTORS; AGE OF ONSET; AGED; ANDROGENS; ANTHROPOMETRY; DRUG MONITORING; GERMANY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; REGISTRIES; SEXUAL BEHAVIOR; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84926456984     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2015.56.4.310     Document Type: Article

References (30)

1. Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl 2014;16:192-202.
2. Pye SR, Huhtaniemi I., Finn JD, Lee DM, O'Neill TW, Tajar A, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014;99:1357-66.
3. Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014;2:819-34.
4. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-80.
5. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
6. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013; 27:557-79.
7. Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 2014;16: 146-52.
8. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014; 8:e339-49.
9. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975-81.
10. Traish A., Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014;68:314-29.
11. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430-9.
12. Heinemann LA. Aging Males' Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005;2811 Suppl to no.11:34-8.
13. Yoon YS, Oh SW. Optimal waist circumference cutoff values for the diagnosis of abdominal obesity in korean adults. Endocrinol Metab (Seoul) 2014;29:418-26.
14. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
15. Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes 2003;1:15.
16. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012;167:531-41.
17. Maggio M, Snyder PJ, De Vita F, Ceda GP, Milaneschi Y, Lauretani F, et al. Effects of transdermal testosterone treatment on inflammatory markers in elderly males. Endocr Pract 2014;20: 1170-7.
18. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren L., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
19. Yassin DJ, El Douaihy Y, Yassin A., Kashanian J, Shabsigh R, Hammerer PG. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 2014;32:1049-54.
20. Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moder ate lower urinary tract symptoms: one year follow-up. World J Mens Health 2013;31:47-52.
21. Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674-9.
22. Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013;81:1325-9.
23. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol 2015;193:80-6.
24. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of followup. N Engl J Med 2012;366:981-90.
25. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23.
26. Morgentaler A. Testosterone deficiency and cardiovascular mortality. Asian J Androl 2015;17:26-31.
27. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Front Horm Res 2014;43:1-20.
28. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165: 675-85.
29. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med 2013;10:1401-9.
30. Donatucci C, Cui Z, Fang Y, Muram D. Long-term treatment patterns of testosterone replacement medications. J Sex Med 2014;11:2092-9.